【US Stock Movement】Alvotech surges on October 5: FDA approval, SIMLANDI expansion, and biosimilar drugs

Alvotech Significant Increase on October 5 Analysis

Keywords: FDA Approval, SIMLANDI Capacity Expansion, Biosimilars

1. On October 5, 2026, the FDA approved the supplemental biologics license application for AVT02, sold in the United States under the brand name SIMLANDI. This approval allows its active pharmaceutical ingredient to be manufactured at the second production facility DSM2 at the Reykjavik site, doubling the US supply capacity and enabling flexible production arrangements between DSM1 and DSM2.

2. On October 5, 2026, Alvotech stated that the approval further confirms that the FDA inspection issues related to the Reykjavik site have been resolved; DSM2 covers the complete API production process, including cell culture and purification, and is already approved for production of AVT02, AVT03, and AVT05 for the European market.

(Disclaimer: This content is collected and summarized from public information using AI technology for reference only and does not constitute investment advice.)